Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-297P refers to a **pseudogene copy of the U6 small nuclear RNA gene**. U6 small nuclear RNA (snRNA) is an essential component of the major spliceosome, the ribonucleoprotein complex that catalyzes pre-mRNA splicing in eukaryotes[1]. The U6 snRNA is highly conserved and critical for RNA processing; however, **RNU6-297P is classified as a pseudogene**, meaning it is a non-functional genomic copy. Pseudogenes like RNU6-297P arise from retrotransposition processes and do not encode a functional RNA. They are not considered therapeutic targets, receptors, enzymes, or any direct functional molecule in cell biology. Rather, such pseudogenes can be used as **markers for retrotransposon (LINE-1) activity** within genomes for evolutionary or genomic studies[3][7]. There is no established direct relationship to disease, drug targeting, or biological pathway involvement for RNU6-297P. If you meant a functional spliceosomal component, the proper target is U6 small nuclear RNA (RNU6-1), but RNU6-297P is a **defunct, non-functional pseudogene** and not a recognized target in pharmacology or molecular therapeutics[4][7].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 297, pseudogene (RNU6-297P).